10:14 AM EST, 01/10/2025 (MT Newswires) -- Pacira Biosciences ( PCRX ) reported preliminary 2024 revenue Friday of $701 million, up from $675 million a year earlier.

Analysts polled by FactSet expect $695.1 million.

The company also outlined a five-year strategy to expand its focus on musculoskeletal pain and related areas, aiming for growth by 2030.

The plan, called 5x30, includes treating more than 3 million patients annually, achieving double-digit annual revenue growth, increasing gross margins by 5 percentage points, advancing five new clinical programs and establishing five partnerships, Pacira said.

Shares of the company jumped 16% in recent Friday trading.

Price: 21.62, Change: +3.04, Percent Change: +16.36